Equities research analysts predict that Cerus Co. (NASDAQ:CERS) will report ($0.12) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Cerus’ earnings. The highest EPS estimate is ($0.10) and the lowest is ($0.13). Cerus also posted earnings of ($0.12) per share during the same quarter last year. The company is expected to announce its next earnings report on Tuesday, February 25th.
On average, analysts expect that Cerus will report full-year earnings of ($0.50) per share for the current year, with EPS estimates ranging from ($0.52) to ($0.46). For the next financial year, analysts forecast that the company will report earnings of ($0.38) per share, with EPS estimates ranging from ($0.46) to ($0.24). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Cerus.
Cerus (NASDAQ:CERS) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The business had revenue of $18.00 million during the quarter, compared to analyst estimates of $17.69 million. Cerus had a negative return on equity of 100.59% and a negative net margin of 100.38%. Cerus’s revenue for the quarter was up 16.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.11) EPS.
Shares of NASDAQ:CERS traded down $0.02 during midday trading on Friday, reaching $4.18. The company’s stock had a trading volume of 36,491 shares, compared to its average volume of 933,202. Cerus has a fifty-two week low of $3.95 and a fifty-two week high of $6.88. The company has a market capitalization of $608.99 million, a P/E ratio of -9.55 and a beta of 1.57. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.77 and a quick ratio of 2.31. The business’s fifty day simple moving average is $4.35 and its 200-day simple moving average is $4.96.
In other news, SVP Carol Moore sold 30,000 shares of the business’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $5.33, for a total transaction of $159,900.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 7.26% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Aperio Group LLC acquired a new position in Cerus in the second quarter valued at approximately $27,000. Meristem Family Wealth LLC bought a new position in Cerus in the second quarter valued at approximately $56,000. Jefferies Group LLC acquired a new stake in Cerus during the 2nd quarter worth $75,000. Jane Street Group LLC acquired a new stake in Cerus during the 2nd quarter worth $93,000. Finally, Cubist Systematic Strategies LLC grew its holdings in Cerus by 1,108.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 20,551 shares of the biotechnology company’s stock worth $115,000 after acquiring an additional 18,851 shares during the period. 75.02% of the stock is owned by institutional investors and hedge funds.
Cerus Company Profile
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Featured Article: Economic Reports
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.